The LDN Shop
Visit our e-commerce website for Conferences, Webinars, Medical Membership, eBooks etc
Journal of Translational Medicine
2024 Jul 5;22(1):630.
Matthias Löhn & Klaus Josef Wirth
Linda Elsegood interviewing Andrea, a patient from the United States who has been taking low dose naltrexone (LDN) to manage her health concerns.
Review Open access Published: 05 July 2024
Volume 22, article number 630, (2024)
Matthias Löhn & Klaus Josef Wirth
Potential pathophysiological role of the ion channel TRPM3 in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) and the therapeutic effect of low-dose naltrexone
05 July 2024, Volume 22, article number 630, (2024)
Matthias Löhn and Klaus Josef Wirth
Journal of Translational Medicine
Addiction Medication Offers New Hope for Long COVID Patients
Featured in Neurology Neuroscience·May 7, 2024
New Research Aims to Unravel Both ME/CFS and Long COVID
Miriam E. Tucker
Medscape Medical News > Conference News
December 21, 2023